Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3017 Patient and Healthcare Practitioner Perspectives of Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review

Introduction: Somatostatin analogs (SSAs) are used to treat acromegaly and neuroendocrine tumors (NETs). Two first-generation SSAs, octreotide and lanreotide, are available to patients (pts).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cella D

Authors: Feuilly M, Jenni E, Cella D,

Keywords: neuroendocrine tumors, acromegaly, preference, patient reported outcomes,

#2969 Lanreotide Autogel and Octreotide LAR Treatment Patterns: Results from a Nationwide French Retrospective Study

Introduction: Lanreotide autogel (LAN) and octreotide LAR (OCT) are long acting somatostatin analogues (LA-SSAs) used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previous studies conducted in North America and Sweden showed some differences between both LA-SSAs in terms of dose and persistence.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Fagnani F, Feuilly M, Marteau F, de Zélicourt M, Kamenicky P,

Keywords: somatostatin analogues, treatment patterns, resource use,

#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis

Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Feuilly M

Authors: Feuilly M, Cristeau O, Clay E, François C, Whalen J,

Keywords: somatostatin analogues, economics,

#2932 Evaluation of Nurse Preferences between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe: An International Simulated Use Study (PRESTO)

Introduction: A new lanreotide autogel/depot (LAN) syringe was developed based on feedback from a human factors study to improve user experience.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Truong Thanh X, Adelman D, Feuilly M, Houchard A, Cella D,

Keywords: Somatuline lanreotide, syringe, neuroendocrine tumors, medical treatment,

#1860 Carcinoid Heart Disease (CHD): Prognostic Value of 5-HIAA and Impact on Survival – A Systematic Literature Review

Introduction: CHD is a life threatening complication of carcinoid syndrome. Its exact pathophysiology is uncertain but several studies have identified serotonin as a potential key mediator. The amount of serotonin production can be assessed by the dosage of its metabolite 5-HIAA in urine or plasma.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Singh S

Authors: Haig J, Kohli M, Pastor L, Feuilly M, Marteau F,

Keywords: 5-HIAA, prognosis, carcinoid heart disease, survival,